The aim of this prospective cohort study is to collect the multi-omics profile of cardiovascular disease (CVD) high-risk individuals in Harbin, and to discover novel biomarker signatures of major adverse cardiovascular events (MACE) during a minimum 2-year follow-up period.
1.Residents of Harbin city, regardless of gender.
2.Meets at least two of the following conditions: diabetes, hypertension, hyperlipidemia, or obesity.
3.No history of cardiovascular or cerebrovascular diseases.
4.Willing to participate in the study and sign the informed consent form
1.History of antibiotic or probiotic treatment within the past month.
2. Pregnant women.
3. History of autoimmune diseases or malignant tumors; severe heart, liver, or kidney dysfunction; or a history of severe cardiovascular or cerebrovascular diseases.
4. Any unstable condition or situation that may jeopardize patient safety or compliance.
The study will enroll 10,000 participants aged 45 and above from Harbin, a city in northeastern China. To be eligible, participants must meet at least two of the following criteria: hypertension, hyperglycemia, hyperlipidemia, or obesity.
Cohort
Prospective
Not listed
Major adverse cardiovascular event (MACE)
A major adverse cardiovascular event (MACE) of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke
Cardiovascular death
Cardiovascular death
All-cause death
All-cause death
Myocardial infarction
Myocardial infarction
Stroke
Stroke
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
